Return to: Academic Health Center : U of M Home

Gold University of Minnesota M. Skip to main content.University of Minnesota. MyU | One Stop | Directories | Search U of M  
Driven to Discover.
Molecular and Cellular Therapy
What's Inside

MCT Home

 
 
  Home > About the MCT > Jeffrey Miller, M.D., Associate Director
 

Jeffrey Miller, M.D., Associate Director

Jeffrey S. Miller, M.D., is professor of medicine, associate scientific director of Molecular and Cellular Therapeutics, program co-director of the transplant biology and therapy program, and director of the translational cell therapy core in the NCI-designated comprehensive Cancer Center at the University of Minnesota. He is an experienced clinical investigator in the field of marrow transplantation and medical director of the inpatient BMT unit. Dr. Miller’s research team works in two areas that seek to understand fundamental issues regarding innate immune function: (1) how undifferentiated stem cells develop into functioning natural killer (NK) lymphocytes, and (2) how to manipulate NK cells to treat or prevent cancer relapse. The second major emphasis in Dr. Miller’s laboratory is based on pre-clinical and clinical studies to develop effective anti-tumor immunotherapies. Early studies focused on nonspecific immune stimulation using subcutaneous interleukin-2 (IL-2).  Strong evidence suggests that this nonspecific therapy alone will be ineffective and current efforts aim to target effectors specifically to tumor cells.  For NK cells, current approaches include use of allogeneic NK cell therapies to overcome inhibitory mechanisms by recognition of “self” class I molecules. To target T-cells, studies have been initiated using cancer vaccines.

Professional Appointment

  • Instructor, Department of Medicine, University of Minnesota Medical School, Minneapolis, Minnesota, 1991-1992

  • Assistant Professor, Department of Medicine, University of Minnesota Medical School, 1992-1997

  • Associate Professor, Department of Medicine, University of Minnesota Medical School, 1997-2001

  • Professor with tenure, Department of Medicine, University of Minnesota Medical School, 2001-present

  • Licensure: Iowa - #25689, Minnesota - #34245

  • Board Certified, Internal Medicine, 9/88, #119492

  • Board Certified, Medical Oncology, 11/91(Recert. 11/01), #119492

  • Board Certified, Hematology, 11/92(Recert. 11/01), #119492 

Professional Affiliations and Activities                                                 

  • International Society of Experimental Hematology, 1992-present

  • American Society of Hematology, 1992-present

  • International Society of Hematotherapy and Graft Engineering, 1993-present

  • Medical Director, Inpatient BMT Unit

  • American Society of Clinical Investigation (ASCI), 1999-present

  • Sponsored IND's:  IND-BB 5708, IND-BB 6544, IND-BB 6545, IND-BB 8847, BB-IND 10430

  • Director, Translational Cell Therapy Core Laboratory, University of Minnesota Cancer Center,1998-present

  • Co-Director, Transplant Biology and Therapy Program Laboratory (Univ. of MN Cancer Center) 2003-present

  • Associate Director, General Clinical Research Center, 2002-present

  • Associate Director, Molecular and Cellular Therapeutics, 2002-present

  • Journal Reviewer: Blood, Experimental Hematology

  • Primary Reviewer Pool: The Journal of Immunology

  • Editorial Board: Experimental Hematology, Journal of Hematotherapy and Stem Cell Research

Publications (Selected from 63 publications)

  • Miller JS, Verfaillie C, McGlave P:  Adherent lymphokine-activated killer (A-LAK) cells suppress autologous human normal bone marrow progenitors.  Blood 77:2389, 1991.

  • Miller JS, Oelkers S, Verfaillie C, McGlave P:  The role of monocytes in the expansion of human activated natural killer cells.  Blood 80:2221-2229, 1992.

  • Miller JS, Verfaillie C, McGlave P:  The generation of natural killer cells from CD34+/DR- primitive progenitors in human long term bone marrow culture.  Blood, 80:2182-2187, 1992.

  • Miller JS, Alley KA, McGlave P:  Differentiation of NK cells from human marrow progenitors in a long term culture system:  Identification of a CD34+7+ NK progenitor.  Blood 83:2594-2601, 1994.

  • Pierson BA, Gupta K, Hu W-S, Miller JS: Human natural killer cell expansion is regulated by thrombospondin- mediated activation of TGF-b1 and independent cell-derived contact and soluble factors.  Blood 87:180, 1996.

  • Cervantes F, McGlave PB, Verfaillie CM, Miller JS: Autologous activated natural killer cells suppress primitive CML progenitors in long term culture.  Blood 87:2476-2485, 1996.

  • Pierson BA, Miller JS:  CD56+bright and CD56+dim natural killer cells progressively decrease in patients with chronic myelogenous leukemia, respond less to stimuli which recruit clonogenic NK, and exhibit decreased proliferation on a per cell basis.  Blood 88:22798-2287, 1996.

  • Miller JS, Tessmer-Tuck J, Pierson BA, Weisdorf D, McGlave PB, Blazar B, Katsanis E, Verfaillie C, Lebkowski J, Radford J, Burns L:  Low dose subcutaneous interleukin-2 after autologous transplantation for lymphoma and breast cancer generates sustained in vivo natural killer cell activity.  Biol. Blood and Marrow Transplant., 3:34-44, 1997.

  • Miller JS, Tessmer-Tuck J, Blake N, Lund J, Scott A, Blazar BR, Orchard P: Endogenous IL-2 production by natural killer cells (NK) maintains cytotoxic and proliferative capacity following retroviral mediated gene transfer.  Exp. Hematology 25:1140-1148, 1997.

  • Miller JS, Prosper F, McCullar V: Natural Killer Cells (NK) are functionally abnormal and NK progenitors are diminished in G-CSF mobilized peripheral blood progenitor cell collections.  Blood 90:3098-3105, 1997.

  • Gaffney P, Lund J, Miller JS:  FLT-3 ligand and marrow stroma derived factors promotes CD3@, CD3@, CD3@ and RAG-2 gene expression in primary human CD34+LIN-DR- marrow progenitors. Blood, 91:1662, 1998.

  • Miller JS, McCullar V, Verfaillie CM: Ex vivo culture of CD34+Lin-DR- cells in stroma derived soluble factors, MIP-1@ and IL3 maintains not only myeloid but also lymphoid progenitors in a novel switch culture assay. Blood 91:4516, 1998.

  • Miller JS, McCullar V, Punzel M, Lemischka IR,  Moore KA:  Single adult human CD34+/Lin-/CD38- cells give rise to NK cells, B-lineage cells, dendritic cells and myeloid cells.  Blood, 93:96-106, 1999.

  • Miller JS, Cervenka T, Lund J, Okazaki IJ, Moss J: Purine metabolites suppress proliferation of human NK cells through a lineage specific P2 purine receptor.  J. Immunology, 162:7376-82, 1999.

  • Cooley S, Burns LJ, Miller JS:  Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody dependent cellular cytotoxicity against LFA-3 and HER2/neu.  Experimental Hematology, 27:1533-1541, 1999.

  • Burns LJ, Weisdorf DJ, DeFor TE, Repka TL, Ogle KM, Hummer C, Miller JS:  Enhancement of the anti-tumor activity of a peripheral blood progenitor cell graft by mobilization with IL-2 plus G-CSF in patients with advanced breast cancer.  Experimental Hematology, 28:96-103, 2000.

  • Toor AA, Lund TC, Miller JS:  T-Cell Factor-1 (TCF-1) Expression During Human NK Cell Development and in Circulating CD56+bright NK Cells.  Exp. Hematology, 29:499-506, 2001, 2001

  • Miller JS, McCullar V:  Human NK cells with polyclonal lectin and immunoglobulin receptors develop from single HSC’s with preferential expression of NKG2A and KIR2DL2/L3/S2.  Blood, 98:705-713, 2001.

  • Miller JS:  The Biology of NK cells in cancer, infection and pregnancy.  Exper. Heme., 29:1157-68, 2001.

  • Nakajima H, Zhao R, Ward J, Dolan M, Hirsch B, Miller JS:  The BCR/ABL transgene causes abnormal NK cell differentiation and can be found in circulating NK cells of advanced CML patients.  J. Immunol. 168:643-650, 2002.

  • Davies SM, Ruggieri L, Defor T, Wagner JE, Weisdorf DJ, Miller JS, Velardi A, Blazar BR: Natural Killer Cell Alloreactivity in Mismatched Unrelated Donor Hematopoietic Transplants.  Blood, 100:3825-27, 2002.

  • Burns LJ, Weisdorf DW, Vesole D, Repka T, Blazar BR, Burger SR, Panoskalysis-Mortari A, Keever-Taylor CA, Zhang MJ, Miller JS:  IL-2 Based Immunotherapy after Autologous Transplantation for Lymphoma and Breast Cancer Induces Immune Activation and Cytokine Release: A Phase I/II Trial. Bone Marrow Transplantation, 32:177-186, 2003.

  • Repka T, Chiorean EG, Gay J, Herwig KE, Kohl VK, Yee D, Miller JS:  Trastuzumab and IL-2 in HER-2 positive Metastatic Breast Cancer: A Pilot Study. Clinical Cancer Research 9:2440-2446, 2003.

  • Chiorean EG, Dylla, SJ, Olsen K, Dylla S, Lenvik T, Miller JS:  BCR/ABL Alters the Function of NK Cells and the Acquisition of Killer Immunoglobulin-like Receptors (KIR). Blood 101:3527, 2003.

  • Barker JN, Weisdorf DJ, DeFor TE, Blazar BR, Miller JS, Wagner JE.  Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning.  Blood, 102:1915-9, 2003

  • Chiorean EG, DeFor TE, Weisdorf DJ, Blazar BR , McGlave PB, Burns LJ, Charlotte Brown C, Miller JS: Donor Chimerism does not Predict Response to DLI for Relapsed CML after Allogeneic Hematopoietic Cell Transplantation, Biology of Blood and Marrow Transplantation, 10:171-77, 2004.

  • Chen W, Chan ASH, Dawson AJ, Liang X,  Blazar BR,  Miller JS: FLT3-ligand administration after hematopoietic cell transplantation increases circulating dendritic cell precursors that can be activated by CpG oligodeoxynucleotides to enhance T-cell and NK-cell function. In Press, Biology of Blood and Marrow Transplantation, 2004.

  • Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, McKenna D, Le C, Defor TE, Burns LJ, Orchard PJ, Blazar BR, Wagner JE, Slungaard A, Weisdorf DJ, Okazaki IJ, McGlave PB: Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in cancer patients. In Press, Publish on-line Blood first addition, 2005.

  • Chen W, Chan ASH,  Dawson AJ, Liang X,  Blazar BR,  Miller JS: FLT3-ligand administration after hematopoietic cell transplantation increases circulating dendritic cell precursors that can be activated by CpG oligodeoxynucleotides to enhance T-cell and NK-cell function. In Press, Biology of Blood and Marrow Transplantation, 11:23-34, 2005.

 

Feedback | Notice of Privacy Practices


©2007-2008 Regents of the University of Minnesota. All rights reserved. Contact U of M | Privacy
The University of Minnesota is an equal opportunity educator and employer. Last modified on June 27, 2008